Validation of a Blood-Based Biomarker Test for the Diagnosis and Management of Bronchopulmonary Neuroendocrine Tumors Abstract #2220

Introduction: There is currently no effective blood biomarker for lung neuroendocrine neoplasia diagnosis and management.
Aim(s): We describe the clinical utility of the NETest to diagnose bronchopulmonary neuroendocrine tumors and define their clinical status.
Materials and methods: The discovery set included BPNETs (n=154) and controls (n=90), randomly assigned [1:1] to a test and validation set. Specificity was evaluated in adenocarcinoma (n=54) and squamous cell carcinoma: (n=37), other NENs (n=13), and COPD: (n=18). Clinical efficacy: disease presence versus absence was assessed in a surgical cohort (n=45) and progressive versus stable disease (n=154). Gene expression (NETest-PCR) and CgA (ELISA-Euro Diagnostica) levels were evaluated by non-parametric, ROC and Fisher’s test.
Conference: 15th Annual ENETS conference (2018)
Category: Non digestive NETs (bronchial, thymic, others) - diagnosis and therapy
Presenting Author: Professor Mark Kidd

To read results and conclusion, please login ...

Further abstracts you may be interested in

#309 The Utility of Alpha Internexin as a Predictive Tissue Biomarker for Proliferation in Gastrointestinal and Pancreatic Neuroendocrine Tumors
Introduction: GEP-NETs are increasing but Ki-67 and CgA provide limited information regarding malignancy. A key unmet need is alternative biomarkers to assess the likelihood of local invasion or metastasis.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: Dr Mark Kidd
#1489 The Clinical Utility of Blood Neuroendocrine Gene Transcript Analysis, the NETest, in Paragangliomas and Pheochromocytomas
Introduction: Diagnosis of disease and identification of progression are critical issues in paraganglioma (PGL) and pheochromocytoma (PCC) management. An accurate blood biomarker that defines tumor biology irrespective of biochemical activity is lacking.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: NETest, PCR
#1497 Circulating Neuroendocrine Tumor Gene Signature, the NETest, Defines Therapy in GEP-NETs
Introduction: Early and precise delineation of therapeutic responses are key issues in GEP-NET management. Imaging has limitations in sensitivity while secretory biomarkers e.g., CgA is controversial.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: NETest, CgA, PCR
#1569 Blood Measurement of NET Transcripts (NETest) Predicts Well-Differentiated Gastroenteropancreatic NET Disease Status and Is Prognostic for Disease Progression
Introduction: A key issue in GEP-NETs is early identification and prediction of disease progression. Clinical evaluation and imaging are limited due to the lack of sensitivity and disease indolence.
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Authors: Pavel M, Jann H, Prasad V, Drozdov I, ...
Keywords: PCR
#1571 Blood Gene Transcript Analysis Diagnoses Bronchopulmonary NETs and Identifies Progressive Disease
Introduction: Broncho-Pulmonary (BP) NETs are pulmonary neoplasms with indolent to aggressive behavior. Imaging, histology and biochemistry are limited in defining malignancy or progression
Conference: 13th Annual ENETS conference (2016)
Category: Biomarkers
Presenting Author: Professor Mark Kidd
Keywords: PCR